IBX

0.00%

4.0¢ imagion biosystems limited

Ann: Quarterly Activities/Appendix 4C Cash Flow Report, page-25

First 25 Last

Share
Profile

Follow
Newbie2015

170 Posts.

56

30/10/22

12:38

Post #: 64480798
Share

Originally posted by Densy: ↑

Hi Newbie and thanks for the reply.

You'll see from that announcement the MRX / MRI detection is preclinical research. I am aware that in preclinical work - including 'phantoms' which are a replica breast - the spions were detectable by both MRX and MRI, and that in mouse models using tumour xenografts and tail-vein spion injections both imaging modalities could detect the spions, which aggregated in the tumour xenografts indicating the targeting ligand was working, too.

What I would like to hear from the company is some clarification in relation to the performance of the HER2 targeting spions - not just that they have the ability to reach the lymph node - and the subsequent detectability of the 'attached' spions using both MRX and MRI in vivo.

This is the first time IBX has been in the clinic and, so far as I can see, we're hearing news about safety and tolerability as well as spion transport to the lymph node, but absolutely nothing about the performance of the product as a diagnostic agent.

While Bob is correct when he says that the company needs to be careful not to jump the gun in proclaiming success, there's also nothing precluding an announcement that: 'In the fist five patients, the HER2 targeting spions were found to have bound to tumour cells and were detectable by both MRI and MRX. While encouraging, these early results do not allow robust conclusions to be drawn and further updates will be provided once the trial's statistical endpoint is known.'

My view is that the need to show caution with trial updates has to be balanced against the need to keep the market informed of progress and to recognise that significant delays in recruitment mean that the current lack of news is seriously testing investor patience, putting huge downward pressure on the SP.

The lack of commentary in relation to product performance needs to be addressed IMO.

Cheers

Densy

Expand

Thank you for your considered response, I really appreciate it. My views are aligned with yours. They really need to address product performance now that they at least have 7 patients and under 3 quarters of cash left. If they do a CR before they release some pretty images , the believers like myself will lose confidence. Surely, they can put caveats and share interim data.

IBX Price at posting: 2.9¢ Sentiment: Buy Disclosure: Held
5 Upvote

0 Great analysis

Reply

Top Stories

CKA

Cokal upgrades infrastructure for BBM ramp-up in Indonesia

WCN

White Cliff jumps 24% on 'bonanza grade' copper rock chips at Rae project, Canada

BCI

BCI reaches close of funding facility for salt-first part of Mardie project

COD

Coda Minerals (ASX:COD) enters rights issue to further exploration in South Australia

RCE

Recce eyes Indonesia for novel anti-infective as Indo-Aus ties grow stronger

Week 40 Wrap: China's nonsensical stimmy hype wanes (shocking!); HotCopper's picks; oil & inflation

BUX

Buxton projects new graphite province discovery at WA Narryer play

NTI

Neurotech knocked back by FDA as agency declares target condition not rare enough for special status

ACW

Actinogen Medical ramps up Alzheimer’s treatment trials, targeting fast-track global approvals

SLS

Solstice Minerals to ramp up drilling campaign at Yarri Gold Project

There are more pages in this discussion • 7 more messages in this thread...

First 25 Last

Add IBX (ASX) to my watchlist

(20min delay)
Last 4.0¢		Change 0.000(0.00%)		Mkt cap ! $1.425M

Open	High	Low	Value	Volume
4.0¢	4.0¢	3.6¢	$27.63K	750.1K

Buyers (Bids)

No.	Vol.	Price($)
2	63865	3.7¢

Sellers (Offers)

Price($)	Vol.	No.
4.0¢	25000	1

View Market Depth

No.	Vol.	Price($)
2	63865	0.037
1	28571	0.035
1	20000	0.034
2	48750	0.033
1	92000	0.032

Price($)	Vol.	No.
0.046	90637	1
0.047	14800	1
0.048	13016	2
0.050	105885	2
0.055	88714	1

Last trade - 13.05pm 04/10/2024 (20 minute delay)

IBX (ASX) Chart

Ann: Quarterly Activities/Appendix 4C Cash Flow Report, page-25

Cokal upgrades infrastructure for BBM ramp-up in Indonesia

White Cliff jumps 24% on 'bonanza grade' copper rock chips at Rae project, Canada

BCI reaches close of funding facility for salt-first part of Mardie project

Coda Minerals (ASX:COD) enters rights issue to further exploration in South Australia

Recce eyes Indonesia for novel anti-infective as Indo-Aus ties grow stronger

Week 40 Wrap: China's nonsensical stimmy hype wanes (shocking!); HotCopper's picks; oil & inflation

Buxton projects new graphite province discovery at WA Narryer play

Neurotech knocked back by FDA as agency declares target condition not rare enough for special status

Actinogen Medical ramps up Alzheimer’s treatment trials, targeting fast-track global approvals

Solstice Minerals to ramp up drilling campaign at Yarri Gold Project

Featured News

Buyers (Bids)

Sellers (Offers)

Featured News

Ann: Quarterly Activities/Appendix 4C Cash Flow Report, page-25

Top Stories

Cokal upgrades infrastructure for BBM ramp-up in Indonesia

White Cliff jumps 24% on 'bonanza grade' copper rock chips at Rae project, Canada

BCI reaches close of funding facility for salt-first part of Mardie project

Coda Minerals (ASX:COD) enters rights issue to further exploration in South Australia

Recce eyes Indonesia for novel anti-infective as Indo-Aus ties grow stronger

Week 40 Wrap: China's nonsensical stimmy hype wanes (shocking!); HotCopper's picks; oil & inflation

Buxton projects new graphite province discovery at WA Narryer play

Neurotech knocked back by FDA as agency declares target condition not rare enough for special status

Actinogen Medical ramps up Alzheimer’s treatment trials, targeting fast-track global approvals

Solstice Minerals to ramp up drilling campaign at Yarri Gold Project

Featured News

Buyers (Bids)

Sellers (Offers)

Featured News